{
  "nctrialId": "HC-1448",
  "title": "A Randomized Double-Blind, Active-Controlled Multi-Center Study of AST-611 (anti-IL-5 antibody) in Patients With Parkinson's Disease",
  "officialTitle": "A Randomized Double-Blind, Active-Controlled Multi-Center Study of AST-611 (anti-IL-5 antibody) in Patients With Parkinson's Disease",
  "sponsor": "Alberta Health Services",
  "indication": "Parkinson's Disease",
  "phase": "Phase 4",
  "fileName": "HC-1448.json",
  "fileSize": 324851,
  "date": "2024-11-19",
  "completionDate": "2028-12-04",
  "drugName": "AST-611 (anti-IL-5 antibody)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Completed",
  "description": "This is a randomized double-blind, active-controlled multi-center study designed to evaluate the efficacy and safety of AST-611 (anti-IL-5 antibody) in patients with Parkinson's Disease. The study will enroll approximately 279 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 25-63 years\n- Confirmed diagnosis of Parkinson's Disease\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1448"
}